Earnings Preview: Intevac

Intevac (NASDAQ:IVAC) is set to give its latest quarterly earnings report on Monday, 2024-02-05. Here’s what investors need…

Intevac (NASDAQ:IVAC) is set to give its latest quarterly earnings report on Monday, 2024-02-05. Here’s what investors need to know before the announcement.

Analysts estimate that Intevac will report an earnings per share (EPS) of $-0.12.

Intevac bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.13, which was followed by a 11.54% increase in the share price the next day.

Here’s a look at Intevac’s past performance and the resulting price change:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate -0.13 -0.21 -0.18 -0.18
EPS Actual 0 -0.19 -0.16 -0.13
Price Change % 11.54% 6.57% -21.65% 1.03%

eps graph

Stock Performance

Shares of Intevac were trading at $4.08 as of February 01. Over the last 52-week period, shares are down 42.45%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Intevac visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Canopy Growth Reports 7% YoY Increase In Q4 Net Revenue, Continues Focus On Innovation In Canada And International Expansion

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) announced on Thursday financial results for the fourth quarter and fiscal year ended March 31, 2024.Fourth quarter net revenue for the company's subsidiary Storz & Bickel which manufactures high-end and medically certified cannabis vaporizers surged 43% year-over-year to CA$22million ($16 million).Moreover, Canada's cannabis net revenue in the same period increased 4% year-over-year led by a 16% increase in the Canada medical cannabis business that saw its 5th consecutive quarter of revenue growth.

CGC